Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis

被引:29
作者
Stern, JNH
Illés, Z
Reddy, J
Keskin, DB
Fridkis-Hareli, M
Kuchroo, VK
Strominger, JL [1 ]
机构
[1] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA
[2] Harvard Univ, Inst Med, Ctr Neurol Dis, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
cop1; HLA-DR; multiple sclerosis; T cells;
D O I
10.1073/pnas.0409022102
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Myelin basic protein (MBP) is a major candidate autoantigen in multiple sclerosis (MS). Its immunodominant epitope, MBP 85-99, forms a complex with human leukocyte antigen (HLA)-DR2 with which multiple sclerosis is genetically associated. Copolymer 1 (Copaxone), a random amino acid copolymer [poly (Y,E,A,K)n] as well as two modified synthetic copolymers [poly (F,Y,A,K)n and poly (V,W,A,K)n] also form complexes with HLA-DR2 (DRA/DRB1*1501) and compete with MBP 85-99 for binding. Moreover, two high-affinity synthetic peptide 15-mers that could inhibit binding even more effectively were previously designed. Here, we show that further-modified peptide 15-mers inhibited even more strongly (in order J5 > J3 > J2) both the binding of MBP 85-99 to HLA-DR2 and IL-2 production by two MBP 85-99-specific HLA-DR2-restricted T cells. J5, J3, and J2 also suppressed both MBP 85-99-induced experimental autoimmune encephalomyelitis (EAE) in humanized mice and proteolipid protein 139-151-induced EAE in SJL/J mice. Moreover, none of these previously uncharacterized peptide inhibitors crossreacted with MBP 85-99- or proteolipid protein 139-151-specific T cells. In both cases, spleen and lymph node cultures stimulated with these peptides produced large amounts of Th2 cytokines (IL-4 and IL-10), and adoptive transfer of established T cell lines suppressed disease induction. These peptide 15-mers provide specific, nonrandom sequences that appear to be at least as effective as random copolymers in suppressing EAE in several models.
引用
收藏
页码:1620 / 1625
页数:6
相关论文
共 43 条
[1]   T-SUPPRESSOR HYBRIDOMAS AND INTERLEUKIN-2-DEPENDENT LINES INDUCED BY COPOLYMER-1 OR BY SPINAL-CORD HOMOGENATE DOWN-REGULATE EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS [J].
AHARONI, R ;
TEITELBAUM, D ;
ARNON, R .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (01) :17-25
[2]   T-CELLS RESPONSIVE TO MYELIN BASIC-PROTEIN IN PATIENTS WITH MULTIPLE-SCLEROSIS [J].
ALLEGRETTA, M ;
NICKLAS, JA ;
SRIRAM, S ;
ALBERTINI, RJ .
SCIENCE, 1990, 247 (4943) :718-721
[3]   IL-10, a key effector regulatory cytokine in experimental autoimmune encephalomyelitis [J].
Bettelli, E ;
Nicholson, LB ;
Kuchroo, VK .
JOURNAL OF AUTOIMMUNITY, 2003, 20 (04) :265-267
[4]  
Bettelli E, 1998, J IMMUNOL, V161, P3299
[5]   Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand [J].
Bielekova, B ;
Goodwin, B ;
Richert, N ;
Cortese, I ;
Kondo, T ;
Afshar, G ;
Gran, B ;
Eaton, J ;
Antel, J ;
Frank, JA ;
McFarland, HF ;
Martin, R .
NATURE MEDICINE, 2000, 6 (10) :1167-1175
[6]   A PILOT TRIAL OF COP-1 IN EXACERBATING REMITTING MULTIPLE-SCLEROSIS [J].
BORNSTEIN, MB ;
MILLER, A ;
SLAGLE, S ;
WEITZMAN, M ;
CRYSTAL, H ;
DREXLER, E ;
KEILSON, M ;
MERRIAM, A ;
WASSERTHEILSMOLLER, S ;
SPADA, V ;
WEISS, W ;
ARNON, R ;
JACOBSOHN, I ;
TEITELBAUM, D ;
SELA, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (07) :408-414
[7]   Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein [J].
Brocke, S ;
Gijbels, K ;
Allegretta, M ;
Ferber, I ;
Piercy, C ;
Blankenstein, T ;
Martin, R ;
Utz, U ;
Karin, N ;
Mitchell, D ;
Veromaa, T ;
Waisman, A ;
Gaur, A ;
Conlon, P ;
Ling, N ;
Fairchild, PJ ;
Wraith, DC ;
OGarra, A ;
Fathman, CG ;
Steinman, L .
NATURE, 1996, 379 (6563) :343-346
[8]   Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions [J].
deRosbo, NK ;
Hoffman, M ;
Mendel, I ;
Yust, I ;
Kaye, J ;
Bakimer, R ;
Flechter, S ;
Abramsky, O ;
Milo, R ;
Karni, A ;
BenNun, A .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (11) :3059-3069
[9]  
Druet P, 1995, Clin Exp Immunol, V101 Suppl 1, P9
[10]  
Fridkis-Hareli M, 1999, J IMMUNOL, V162, P4697